Wealthcare Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Wealthcare Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	-$1K	–	540
2021 Q1	$1K	Buy	+3	New	+$1.46K	﹤0.01%	714
2020 Q1	–	Sell	-7	Closed	-$3K	–	553
2019 Q4	$3K	Buy	+7	New	+$2.35K	﹤0.01%	367
2015 Q3	–	Sell	-3	Closed	-$2K	–	355
2015 Q2	$2K	Hold	3	–	–	﹤0.01%	333
2015 Q1	$1K	Buy	+3	New	+$1.27K	﹤0.01%	881

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Wealthcare Capital Management's REGN Position: Q2 2021 in Review

Wealthcare Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 3 shares — an estimated $1K sold.

Wealthcare Capital Management first reported a position in REGN in Q1 2015 and held it in 4 quarters. The position peaked at $3K in Q4 2019. 972 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

Wealthcare Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wealthcare Capital Management sold 3 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $1K.
Wealthcare Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 4 quarters.
Wealthcare Capital Management's Regeneron Pharmaceuticals position peaked at $3K in Q4 2019.
972 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Wealthcare Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.